ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL429
CHEMBL429
Compound Name LABETALOL
ChEMBL Synonyms LABROCOL | Normodyne | LABETALOL | Trandate | LABETALOL HYDROCHLORIDE | LABETALOL HYDROCLORIDE | SCH 15719W | AH 5158A | Normozide | NORMODYNE | TRANDATE
Max Phase 4 (Approved)
Trade Names LABETALOL HYDROCLORIDE | TRANDATE | NORMODYNE | LABETALOL HYDROCHLORIDE | LABROCOL
Molecular Formula C19H24N2O3

Additional synonyms for CHEMBL429 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CC(CCc1ccccc1)NCC(O)c2ccc(O)c(c2)C(=O)N
Standard InChI InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15 ...
Download InChI
Standard InChI Key SGUAFYQXFOLMHL-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • DrugMatrix
  • Gene Expression Atlas Compounds
  • Open TG-GATEs
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL429

Molecule Features

CHEMBL429 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Racemic Mixture Prodrug:N Oral:Y Parenteral:Y Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Adrenergic receptor antagonist Adrenergic receptor DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Tobacco Use DisorderD014029EFO:0003768nicotine dependence2ClinicalTrials
Cerebral HemorrhageD002543EFO:0005669intracerebral hemorrhage2ClinicalTrials
ClinicalTrials
HypertensionD006973EFO:0000537hypertension3ClinicalTrials
HypotensionD007022EFO:0005251hypotension0ClinicalTrials
StrokeD020521EFO:0000712stroke2ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease4ATC
Pre-EclampsiaD011225EFO:0000668preeclampsia2ClinicalTrials
ClinicalTrials
Acute Coronary SyndromeD054058EFO:0005672acute coronary syndrome0ClinicalTrials
Cocaine-Related DisordersD019970EFO:0002610cocaine dependence2ClinicalTrials

Clinical Data

ClinicalTrials.gov LABETALOL
The Cochrane Collaboration LABETALOL

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL429. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL213 Beta-1 adrenergic receptor Homo sapiens 1.000
CHEMBL210 Beta-2 adrenergic receptor Homo sapiens 1.000
CHEMBL246 Beta-3 adrenergic receptor Homo sapiens 1.000
CHEMBL5414 Beta-2 adrenergic receptor Cavia porcellus 1.000
CHEMBL4400 Beta-3 adrenergic receptor Canis lupus familiaris 0.999
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.630
CHEMBL3252 Beta-1 adrenergic receptor Rattus norvegicus 0.436
CHEMBL3373 Beta-2 adrenergic receptor Bos taurus 0.316



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL210 Beta-2 adrenergic receptor Homo sapiens 1.000
CHEMBL246 Beta-3 adrenergic receptor Homo sapiens 1.000
CHEMBL213 Beta-1 adrenergic receptor Homo sapiens 1.000
CHEMBL5414 Beta-2 adrenergic receptor Cavia porcellus 1.000
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 1.000
CHEMBL3252 Beta-1 adrenergic receptor Rattus norvegicus 1.000
CHEMBL4400 Beta-3 adrenergic receptor Canis lupus familiaris 0.999
CHEMBL3373 Beta-2 adrenergic receptor Bos taurus 0.986
CHEMBL5857 Trace amine-associated receptor 1 Homo sapiens 0.320

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
328.4 328.1787 2.14 8 95.58 BASE


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
4 4 0 5 5 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
8.21 9.3 2.72 .83 2 24 0.6

Structural Alerts

There are 1 structural alerts for CHEMBL429. To view alerts please click here.

Compound Cross References

ATC C - CARDIOVASCULAR SYSTEM
C07 - BETA BLOCKING AGENTS
C07A - BETA BLOCKING AGENTS
C07AG - Alpha and beta blocking agents
C07AG01 - labetalol

ChemSpider ChemSpider:SGUAFYQXFOLMHL-UHFFFAOYSA-N
DailyMed labetalol hydrochloride
PubChem SID: 90341718
Wikipedia Labetalol

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL429



ACToR 36894-69-6
Atlas labetalol
BindingDB 25758
ChEBI 6343
DrugBank DB00598
DrugCentral 1531
eMolecules 653717
EPA CompTox Dashboard DTXSID2023191
Guide to Pharmacology 7207
Human Metabolome Database HMDB0014736
IBM Patent System 1D4E58673678E1F5AC6D368DD3531490
KEGG Ligand C07063
LINCS LSM-1282
Mcule MCULE-6427232261
MolPort MolPort-003-898-140
Nikkaji J19.703C
PharmGKB PA164743150
PubChem 3869
PubChem: Thomson Pharma 14777379
SureChEMBL SCHEMBL4582

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/SGUAFYQXFOLMHL-UHFFFAOYSA-N spacer
spacer